Cargando…

Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro

Strategies for driving white adipose tissue (WAT) to acquire brown-like characteristics are a promising approach to reduce obesity. Liraglutide has been reported to active brown adipose tissue (BAT) thermogenesis and WAT browning by rapid intracerebroventricular injection in mice. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Endong, Yang, Yang, Zhang, Juanjuan, Li, Yongmei, Li, Chunjun, Chen, Liming, Sun, Bei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348377/
https://www.ncbi.nlm.nih.gov/pubmed/27835589
http://dx.doi.org/10.18632/oncotarget.13189
_version_ 1782514214060949504
author Zhu, Endong
Yang, Yang
Zhang, Juanjuan
Li, Yongmei
Li, Chunjun
Chen, Liming
Sun, Bei
author_facet Zhu, Endong
Yang, Yang
Zhang, Juanjuan
Li, Yongmei
Li, Chunjun
Chen, Liming
Sun, Bei
author_sort Zhu, Endong
collection PubMed
description Strategies for driving white adipose tissue (WAT) to acquire brown-like characteristics are a promising approach to reduce obesity. Liraglutide has been reported to active brown adipose tissue (BAT) thermogenesis and WAT browning by rapid intracerebroventricular injection in mice. In this study, we investigated the effects and possible mechanisms of liraglutide on WAT browning by chronic treatment. Here, we show that liraglutide significantly decreases body weight of mice and reduces the size of white adipocytes. By quantity polymerase chain reaction, immunoblotting analysis, cell immunofluorescence or immunocytochemical staining, we found liraglutide induced WAT browning because it up-regulated lipolytic activity, BAT, as well as mitochondrial marker genes in inguinal and peripheral renal WAT. We also confirmed liraglutide induced browning of 3T3-L1 because it enhanced expression of BAT and mitochondrial specific genes. In further, we observed that, soluble guanylyl cyclase (sGC) and protein kinase G I (PKGI) were up-regulated by liraglutide in vivo and in vitro; stimulation of sGC elevated expression of BAT markers and PKGI, which suggested that liraglutide induced WAT browning via sGC-dependent pathway. Taken together, this study expands our knowledge on the mechanism of liraglutide inducing WAT browning, and provides a theoretical support for clinical usage of liraglutide on obesity treatment.
format Online
Article
Text
id pubmed-5348377
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53483772017-03-31 Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro Zhu, Endong Yang, Yang Zhang, Juanjuan Li, Yongmei Li, Chunjun Chen, Liming Sun, Bei Oncotarget Research Paper Strategies for driving white adipose tissue (WAT) to acquire brown-like characteristics are a promising approach to reduce obesity. Liraglutide has been reported to active brown adipose tissue (BAT) thermogenesis and WAT browning by rapid intracerebroventricular injection in mice. In this study, we investigated the effects and possible mechanisms of liraglutide on WAT browning by chronic treatment. Here, we show that liraglutide significantly decreases body weight of mice and reduces the size of white adipocytes. By quantity polymerase chain reaction, immunoblotting analysis, cell immunofluorescence or immunocytochemical staining, we found liraglutide induced WAT browning because it up-regulated lipolytic activity, BAT, as well as mitochondrial marker genes in inguinal and peripheral renal WAT. We also confirmed liraglutide induced browning of 3T3-L1 because it enhanced expression of BAT and mitochondrial specific genes. In further, we observed that, soluble guanylyl cyclase (sGC) and protein kinase G I (PKGI) were up-regulated by liraglutide in vivo and in vitro; stimulation of sGC elevated expression of BAT markers and PKGI, which suggested that liraglutide induced WAT browning via sGC-dependent pathway. Taken together, this study expands our knowledge on the mechanism of liraglutide inducing WAT browning, and provides a theoretical support for clinical usage of liraglutide on obesity treatment. Impact Journals LLC 2016-11-07 /pmc/articles/PMC5348377/ /pubmed/27835589 http://dx.doi.org/10.18632/oncotarget.13189 Text en Copyright: © 2016 Zhu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhu, Endong
Yang, Yang
Zhang, Juanjuan
Li, Yongmei
Li, Chunjun
Chen, Liming
Sun, Bei
Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
title Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
title_full Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
title_fullStr Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
title_full_unstemmed Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
title_short Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
title_sort liraglutide suppresses obesity and induces brown fat-like phenotype via soluble guanylyl cyclase mediated pathway in vivo and in vitro
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348377/
https://www.ncbi.nlm.nih.gov/pubmed/27835589
http://dx.doi.org/10.18632/oncotarget.13189
work_keys_str_mv AT zhuendong liraglutidesuppressesobesityandinducesbrownfatlikephenotypeviasolubleguanylylcyclasemediatedpathwayinvivoandinvitro
AT yangyang liraglutidesuppressesobesityandinducesbrownfatlikephenotypeviasolubleguanylylcyclasemediatedpathwayinvivoandinvitro
AT zhangjuanjuan liraglutidesuppressesobesityandinducesbrownfatlikephenotypeviasolubleguanylylcyclasemediatedpathwayinvivoandinvitro
AT liyongmei liraglutidesuppressesobesityandinducesbrownfatlikephenotypeviasolubleguanylylcyclasemediatedpathwayinvivoandinvitro
AT lichunjun liraglutidesuppressesobesityandinducesbrownfatlikephenotypeviasolubleguanylylcyclasemediatedpathwayinvivoandinvitro
AT chenliming liraglutidesuppressesobesityandinducesbrownfatlikephenotypeviasolubleguanylylcyclasemediatedpathwayinvivoandinvitro
AT sunbei liraglutidesuppressesobesityandinducesbrownfatlikephenotypeviasolubleguanylylcyclasemediatedpathwayinvivoandinvitro